VitaSpring Biomedical Co. Ltd.
VSBC
$0.01
-$0.24-95.56%
OTC PK
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 10/31/2022 | 10/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 109.87% | 109.87% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 109.87% | 109.87% |
| Cost of Revenue | -- | -- | -- | 77.68% | 77.68% |
| Gross Profit | -- | -- | -- | 184.77% | 184.77% |
| SG&A Expenses | -- | -- | -- | 11.70% | 11.74% |
| Depreciation & Amortization | -- | -- | -- | 375.00% | 375.00% |
| Other Operating Expenses | -- | -- | -- | 33.33% | 33.33% |
| Total Operating Expenses | -- | -- | -- | 56.99% | 57.00% |
| Operating Income | -- | -- | -- | 2,398.24% | 2,397.65% |
| Income Before Tax | -- | -- | -- | 2,334.03% | 2,333.46% |
| Income Tax Expenses | -- | -- | -- | 536.94% | 536.94% |
| Earnings from Continuing Operations | -- | -- | -- | 27,429.41% | 27,420.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 27,429.41% | 27,420.59% |
| EBIT | -- | -- | -- | 2,398.24% | 2,397.65% |
| EBITDA | -- | -- | -- | 624.89% | 624.76% |
| EPS Basic | -- | -- | -- | 2,150.00% | 2,150.00% |
| Normalized Basic EPS | -- | -- | -- | 3,500.00% | 3,500.00% |
| EPS Diluted | -- | -- | -- | 2,150.00% | 2,150.00% |
| Normalized Diluted EPS | -- | -- | -- | 3,500.00% | 3,500.00% |
| Average Basic Shares Outstanding | -- | -- | -- | -5.12% | -5.12% |
| Average Diluted Shares Outstanding | -- | -- | -- | -5.12% | -5.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |